TIDMRENE

RNS Number : 4657L

ReNeuron Group plc

03 January 2023

ReNeuron Group plc

("ReNeuron", the "Group" or the "Company")

Total Voting Rights

At 31 December 2022, the Company had 57,173,760 Ordinary Shares in issue, each carrying one voting right.

As the Company holds no ordinary shares in treasury, the figure of 57,173,760 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

ENDS

Contacts:

 
 ReNeuron                                                      www.reneuron.com/investors 
 Iain Ross, Executive Chairman                                            Via Walbrook PR 
 John Hawkins, Chief Financial 
  Officer 
 
 
 Liberum Capital Limited (NOMAD and 
  Joint Broker) 
  Phil Walker (Investment Banking) 
  Richard Lindley (Investment Banking) 
  Ben Cryer (Investment Banking)                                      +44 (0)20 3110 2000 
 
 Allenby Capital Limited (Joint                                       +44 (0)20 3328 5656 
  Broker) 
 James Reeve/George Payne (Corporate 
  Finance) 
 Stefano Aquilino (Sales & Corporate 
  Broking) 
 
 Walbrook PR (Media & Investor             +44 (0)20 7933 8780 or reneuron@walbrookpr.com 
  Relations) 
 Paul McManus / Alice Woodings                          +44 (0)7980 541 893 / +44 (0)7407 
                                                                                  804 654

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell derived Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Group has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

The Group has out-licensed its CTX programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-license both of these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRGZGGMNFMGFZG

(END) Dow Jones Newswires

January 03, 2023 02:02 ET (07:02 GMT)

Grafico Azioni Reneuron (AQSE:RENE.GB)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Reneuron
Grafico Azioni Reneuron (AQSE:RENE.GB)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Reneuron